Inflammopharmacology最新文献

{"title":"Fabrication of bergapten loaded microneedle patch and assessment of its anti-arthritic potential against complete Freund's adjuvant induced arthritis in Wistar rat.","authors":"Qadeer Ahmad, Ammara Saleem, Zulcaif Ahmad, Muhammad Furqan Akhtar","doi":"10.1007/s10787-025-01962-0","DOIUrl":"https://doi.org/10.1007/s10787-025-01962-0","url":null,"abstract":"<p><p>This research study was designed to fabricate bergapten-loaded biodegradable microneedle patches (BP-MNPs) and assess its anti-arthritic potential. The BP-MNPs were synthesized by solvent casting technique using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) as polymers, followed by their characterization. The in vitro release study and stability study were also conducted. X-ray diffraction analysis of BP-MNPs showed a broad range of crystallographic planes, while SEM analysis showed unfractured, sharp tips with a length of 500 µm and a base of 200 µm. The anti-arthritic potential of BP-MNPs was investigated by inserting 0.15 ml of Complete Freund's adjuvant (CFA) into the tail vein of Wistar rats on day 1 to develop a CFA-induced arthritic model. Treatment begins on the 8th day and continues till the 28th day. Methotrexate was administered orally (1 mg/kg) as the standard treatment. The BP-MNPs significantly (p < 0.001-0.0001) decreased paw swelling, arthritic scoring, pain, and restored body weight compared to orally administered bergapten and the standard treatment. The blood parameters were also restored by BP-MNPs, along with the restoration of oxidative stress biomarkers in liver homogenate and neurotransmitter levels in sciatic nerve homogenate. Treatment with BP-MNPs notably (p < 0.0001) reduced the mRNA expression of IL-6, COX-2, TNF-α, and NF-κB, while upregulating IL-4 in contrast to disease control and standard treatment groups. Treatment with BP-MNPs also improved the histology of the ankle joint and sciatic nerve. It can be concluded from the current study data that BP-MNPs at a dose of 10 mg/kg exhibited significant anti-arthritic and anti-nociceptive responses in arthritic rats in contrast to bergapten and the standard drug.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of cyclosporine in colitis: An updated meta-analysis of randomized control trials (1998 to 2024).","authors":"Aqsa Mehreen, Faiza Batool, Uzma Azeem Awan, Shaista Aslam, Adnan Haider, Muneeb Ullah, Jin-Wook Yoo, Rida Fatima Saeed, Muhammad Naeem","doi":"10.1007/s10787-025-01988-4","DOIUrl":"https://doi.org/10.1007/s10787-025-01988-4","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) is a chronic inflammatory condition affecting the large intestine that can progress to colorectal cancer if left untreated. Different therapeutic approaches are used for its treatment and cyclosporine is one of them. It has been investigated as a rescue treatment option in cases when patients are unresponsive to steroidal therapy. However, its efficacy and safety remain uncertain. This study aims to conduct a comprehensive analysis of clinical evidence on cyclosporine safety and efficacy for the treatment of UC.</p><p><strong>Methods: </strong>Electronic databases, Cochrane Library, and PubMed were searched from 1998 till December 2024 to screen the relevant studies. A systematic approach was followed to pool and analyze the studies following the PICOS framework (population, intervention, comparison, outcome, and study design). Data was extracted systematically and analyzed using Comprehensive Meta-analysis software (CMA version 3), with the risk of bias evaluated using the RoB-2 tool, heterogeneity measured using I² statistic, and Publication bias was evaluated using funnel plots and Egger's test.</p><p><strong>Results: </strong>Out of 27 studies initially identified, 6 studies meeting the eligibility criteria were included in the final analysis. The risk of bias was high in four studies for all the outcomes except for colectomy rates. Heterogeneity between studies was not significant for all outcomes. Analysis results demonstrated that there was no statistically significant difference between the clinical response (OR = 1.290, 95%CI 0.552-3.012, P = 0.557), colectomy rates (OR = 1.171, 95%CI 0.776-1.767, P = 0.452), and serious adverse events (OR = 0.592, 95%CI 0.313-1.120, P = 0.107) of cyclosporine in comparison with control group.</p><p><strong>Conclusion: </strong>There is no statistically significant difference between cyclosporine compared to the control group in improving clinical outcomes for patients with ulcerative colitis. Future studies with larger sample sizes can explore its role with combination therapy in targeted patient sub-groups.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies.","authors":"Soumya Mishra, Ranjit K Harwansh, Rupa Mazumder","doi":"10.1007/s10787-025-01997-3","DOIUrl":"https://doi.org/10.1007/s10787-025-01997-3","url":null,"abstract":"<p><p>Gout is a disorder of metabolism characterized by the deposition of urine crystals, and hyperuricemia, the treatment of which was uricosuric agent and xanthine oxidase inhibitor. Recently, attention has been paid to inhibitors of urate transporters, especially URAT1 and GLUT9, for the possibility of increasing uric acid excretion and decreasing serum uric acid levels in the last few years. The article discusses the physiological functions of URAT1 and GLUT9, genetic associations of these proteins with gout, and novel applications of drug delivery aimed at these proteins. This review comprises of clinical reports, and pharmacology updates regarding urate transporters and transport inhibitors. The role of genetic variants on the functioning of transporters were established and novel drug formulations were examined. The article discusses innovations in drug-delivery systems including sustained-release devices, liposomes, and nanoparticles to circumvent pharmacokinetic limitations and improve therapeutic efficacy. The advent of gene therapy and CRISPR editing for the modification of transporters could also be promising for the treatment of hyperuricemia. The integration of transporter-targeted therapy and new drug delivery systems may dramatically change the landscape of gout treatment in terms of safety and personalized treatment options.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ozone therapy for temporomandibular joint osteoarthritis: a comment on the mechanistic insights and clinical translation.","authors":"DuJiang Yang, Jian Wu, Junjie Chen, Shuang Wang, Gaowen Gong, GuoYou Wang","doi":"10.1007/s10787-025-01992-8","DOIUrl":"https://doi.org/10.1007/s10787-025-01992-8","url":null,"abstract":"","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating pomegranate seed oil for potential topical applications: safety, anti-inflammatory activity and wound healing in skin cell models.","authors":"Eduardo M Costa, Manuela Machado, Manuela Pintado, Sara Silva","doi":"10.1007/s10787-025-02002-7","DOIUrl":"https://doi.org/10.1007/s10787-025-02002-7","url":null,"abstract":"<p><p>Pomegranate seed oil (PSO), a by-product of pomegranate juice production, has a long-standing role in traditional medicine, yet is mechanistic and pharmaceutical potential for skin applications remains unexplored. This work explored the bioactivity of PSO in human keratinocytes (HaCaT) and dermal fibroblasts (HDFa) through evaluation of its impact upon cellular metabolism, anti-inflammatory properties and wound healing capacity. The data obtained showed that PSO exhibited no cytotoxic effects up to 500 µg/mL and significantly suppressed pro-inflammatory cytokines (IL-6, IL-8, TNF-α) under LPS-induced inflammatory conditions. Furthermore, wound closure in fibroblasts was accelerated by approximately 20% in a 24-h period. Although antioxidant activity was limited under induced oxidative stress, PSO exerted mild protective effects under basal conditions and fatty acid profiling revealed a PUFA-rich composition, including dihomolinolenic and punicic acids, potentially linked to the observed impact upon cellular metabolism. Overall, these findings offer novel insights into PSO's dual functionality in skin regeneration and immune modulation, supporting its application as a bioactive ingredient for advanced topical therapies.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoencapsulated Syzygium aromaticum oil alleviates acetic acid-induced ulcerative colitis in rats by influencing critical redox, NF-κB/iNOS, and Keap1/Nrf2/HO-1 signaling pathways.","authors":"Gehad E Elshopakey, Shaymaa Rezk, Ahmed Ateya, Tarek A Elkhooly, Alaa A Omar, Ali El-Far, Ekramy M Elmorsy, Hala Magdy Anwer, Mona M Elghareeb","doi":"10.1007/s10787-025-01939-z","DOIUrl":"https://doi.org/10.1007/s10787-025-01939-z","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is an autoimmune inflammatory condition characterized by significant mucosal destruction. Although Syzygium aromaticum (Clove oil; CO) oil is well-known for its antioxidant and anti-inflammatory properties, its high volatility, toxicity, and hydrophobicity can compromise its biological efficacy. Therefore, nanoencapsulation is a feasible approach for boosting its therapeutic potential, including stability, bioavailability, and target delivery. Herein, this study was designed to minimize acetic acid-mediated UC using CO alone or encapsulated in nano-vehicles including PCL, CS, and ALG. The developed nano-capsules CO were characterized by Zetasizer, FT-IR, and SEM, and subsequently, the encapsulation efficiency and controlled release profile of CO were determined. Forty adult rats were assigned to five groups (n = 8) as follows: the control (CONT) group, which received dimethyl sulfoxide (DMSO) once daily; the UC group, which received rectal acetic acid (AA) instillation on day 8 of the experiment. CO group: rats were treated orally with clove oil (250 mg/kg) dissolved in DMSO once daily. PCL@CS + ALG group; rats were orally treated with nano-vehicle (250 mg/kg). CONPs group: rats received clove oil nanoparticles (PCL@CO(CS + ALG)NPs, 250 mg/kg). All groups received their respective treatments once a day for seven consecutive days, before and after UC induction. An in silico study revealed the binding affinities of eugenol, the principal bioactive constituent of CO, toward inflammatory molecules at both the mRNA and protein levels. Biologically, the colon outcomes showed that CO, either alone or loaded with nanoparticles (CONPs), significantly decreased MDA and NO levels and elevated antioxidant enzymatic activities (SOD, CAT, , GPx, and GR), with higher GSH levels. Additionally, the treatment of rats with CO or CONPs mitigated colon inflammation by decreasing the MPO activity, TNF-α, IFN-γ, IL-1β, and PGE2 levels, as well as downregulating the expression of NF-κB, IL-6, IL-8, and iNOS genes. Remarkably, CONPs prevented the colon oxidative damage by modulating the mRNA expression of Keap1/Nrf2/HO-1 signaling pathways. Unlike the rats exposed to AA, the treatment with CO and CONPs dramatically restored the mRNA expression of Cdc25c and RNF8 genes. Histologically, the CONPs-treated group showed a clear restoration of colonic tissue architecture toward normal, accompanied by normalization of VEGF and α-SMA immunoexpression patterns. Conclusively, CO, either alone or encapsulated in nanoparticles (CONPs), offers promising therapeutic potential for UC, likely through its anti-inflammatory, antioxidant, and anti-fibrotic effects, as well as superior regulation of angiogenesis compared with pure CO.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvia argentea L. extract inhibits the production of NO, and pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), alleviates the inflammatory response of LPS-induced macrophages cells, and reduces the CRP level on carrageenan-induced paw edema.","authors":"Almonther Alhamedi, Tugce Demiroz Akbulut, Sura Baykan, Barış Gümüştaş, Ebru Sanci, Karrar Ali Mohammed Hasan Alsakini, Ayşe Nalbantsoy, Aylin Buhur, Altuğ Yavasoğlu, N Ülkü Karabay Yavasoğlu","doi":"10.1007/s10787-025-01942-4","DOIUrl":"https://doi.org/10.1007/s10787-025-01942-4","url":null,"abstract":"<p><p>Salvia argentea L. (Lamiaceae) is a medicinal plant originating from the Mediterranean region and has been used since ancient times for the treatment of various diseases. This study aimed to determine the phytochemical composition of S. argentea L. ethanol extract and to evaluate its in vitro and in vivo anti-inflammatory activity and its acute oral toxicity. The chemical constituents of the ethanol extract prepared from the aerial parts of the plant were identified using HPLC. The in vitro anti-inflammatory activity of the extract was evaluated in LPS-stimulated murine macrophage RAW 264.7 cells and the human monocytic cell line THP-1 by measuring the levels of nitric oxide (NO), pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α). Acute toxicity of the extract was assessed in accordance with OECD guideline no 423. In vivo anti-inflammatory activity was evaluated based on the inhibition of 1% carrageenan-induced paw edema in rats. Serum CRP levels as an inflammatory marker, were measured via ELISA. Histological and immunohistochemical assessments were performed to identify tissue changes in the paw. HPLC profiling revealed that the extract contained rosmarinic acid (11.334 µg/mg dry extract), and salvigenin (2.74 µg/mg of dry extract) as major compounds. The extract significantly inhibited the production of NO, IL-1β, IL-6, and TNF-α without affecting cell viability. In vivo, the extract treatment exhibited a dose-dependent reduction in paw edema and serum CRP levels, along with notable histological improvements. Administration of the extract resulted in dose-dependent decreases of NF-κB expressions in the paw tissues. No signs of acute toxicity were observed (oral LD₅₀ > 2000 mg/kg). These findings suggest that S. argentea L. ethanol extract possesses significant anti-inflammatory potential supporting its possible development as a natural therapeutic agent for inflammatory disorders.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chloroquine protects against mesenteric ischemia: insights into the role of nitrergic and opioidergic systems.","authors":"Seyed Amir Mahdi Emami, Amirabbas Mohammadi Hamaneh, Moein Ghasemi, Alireza Abdollahi, Kimiya Jouyban, Razieh Mohammad Jafari, Amir Hossein Abdolghaffari, Ahmad Reza Dehpour","doi":"10.1007/s10787-025-01842-7","DOIUrl":"https://doi.org/10.1007/s10787-025-01842-7","url":null,"abstract":"<p><strong>Background: </strong>Acute mesenteric ischemia is a severe condition with high mortality and no established pharmacological treatment, driven by oxidative stress, inflammation, and microvascular dysfunction. Chloroquine, an immunomodulatory agent, has shown protective effects in ischemic models, but its role in mesenteric ischemia and its interaction with regulatory pathways remain unclear.</p><p><strong>Objective: </strong>To evaluate protective effects of chloroquine in mesenteric ischemia and its interaction with the nitrergic and opioidergic systems.</p><p><strong>Methods: </strong>Eighty-four male Wistar rats were randomly assigned to fourteen groups and subjected to sixty minutes of mesenteric artery occlusion, followed by sixty minutes of reperfusion. Chloroquine (1-10 mg/kg) was administered, with the minimal effective dose (5 mg/kg) combined with a nitric oxide synthase inhibitor, a nitric oxide precursor, or an opioid receptor antagonist or agonist. Histopathological assessments and biochemical analyses of oxidative and inflammatory markers were conducted.</p><p><strong>Results: </strong>Chloroquine at 5 and 10 mg/kg significantly reduced histopathological scores, with the 5 mg/kg dose associated with increased glutathione and reduced malondialdehyde, myeloperoxidase, tumor necrosis factor-alpha, interleukin-6, and nuclear factor kappa B levels. The opioidergic system contributed to antioxidant effects, enhancing reductions in malondialdehyde and nitric oxide levels, while increasing glutathione levels. In contrast, its anti-inflammatory properties were influenced by the nitrergic pathway, as indicated by increased nuclear factor kappa B levels and histopathological scores upon N(ω)-nitro-L-arginine methyl administration.</p><p><strong>Conclusion: </strong>Chloroquine protects against mesenteric ischemia by modulating oxidative and inflammatory pathways, with the opioidergic and nitrergic systems mediating its effects. These findings highlight a potential therapeutic role for chloroquine, warranting further investigation.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory potential of telmisartan compared to other antihypertensives: secondary outcomes from a randomized trial.","authors":"Simi Bridjit Gomaz, Jaykaran Charan, Amal Mohandas, Pravesh Aggarwal, Deepak Kumar, Dharmveer Yadav, Ravindra Shukla, Sneha Ambwani, Rimple Jeet Kaur","doi":"10.1007/s10787-025-01995-5","DOIUrl":"https://doi.org/10.1007/s10787-025-01995-5","url":null,"abstract":"<p><strong>Background: </strong>Chronic low-grade inflammation plays a central role in the pathophysiology of both type 2 diabetes mellitus (T2DM) and hypertension, contributing to increased cardiovascular risk. Telmisartan, an angiotensin receptor blocker with partial peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist activity, may offer anti-inflammatory benefits in addition to its antihypertensive effects.</p><p><strong>Aims: </strong>This study compares the effects of telmisartan versus other standard antihypertensive agents on inflammatory biomarkers, including high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α), in patients with diabetes and newly diagnosed hypertension.</p><p><strong>Methods: </strong>This is a randomized, open-label, parallel-group, active-controlled trial. Seventy eligible patients were randomized to receive telmisartan (N = 34) or another antihypertensive agent [amlodipine (n = 22), cilnidipine (n = 12), or ramipril (n = 2)] (N = 36). Secondary outcome parameters included inflammatory biomarkers such as highly sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α) measured at baseline and 12 weeks following treatment. Data are presented as median and interquartile range (IQR). Between-group comparisons at 12 weeks were performed using the Mann-Whitney U test. The trial is registered with the Clinical Trial Registry of India (CTRI/2023/04/051878).</p><p><strong>Results: </strong>At baseline, hsCRP, IL-6, and TNF-α levels were comparable between groups. In the telmisartan group, hsCRP declined from 3.4 mg/L (IQR: 2.0, 13.7) to 1.8 mg/L (IQR: 1.2, 5.0), IL-6 from 4.3 pg/mL (IQR: 2.9,9.5) to 3.4 pg/ml (IQR: 2.2, 6.8), and TNF-α from 19.4 pg/ml (IQR: 8.9, 43.7) to 13.8 pg/ml (IQR: 3.5, 32.4). In the active control group, hsCRP changed from 3.1 mg/L (IQR: 1.7, 8.0) to 2.9 mg/L (IQR: 1.7, 4.9), IL-6 from 4.1 pg/ml (IQR: 3.0,7.6) to 4.2 pg/ml (IQR: 2.9, 7.8), and TNF-α from 20.2 pg/ml (IQR: 10.4, 48.6) to 16.9 pg/ml (IQR: 3.3, 30.3). The differences between groups at 12 weeks were not statistically significant for hsCRP (P = 0.07), IL-6 (P = 0.24), or TNF-α (P = 0.93).</p><p><strong>Conclusion: </strong>The anti-inflammatory markers were reduced in both groups at 12 weeks without any statistically significant difference across groups. However, telmisartan was associated with greater reductions in hsCRP, IL-6, and TNF-α in patients with T2DM and hypertension following 12 weeks of treatment. These findings may indicate a potential anti-inflammatory effect of telmisartan that requires confirmation in adequately powered trials.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin: multifaceted biological actions and therapeutic implications-a narrative review.","authors":"Behnam Ghorbani-Nejad, Matin Baghani, Sajad Amiri, Nasim Agaei Delche, Mohammad Hossein Darijani, Motahareh Soltani, Alireza Nezami, Milad Rahimzadegan","doi":"10.1007/s10787-025-01932-6","DOIUrl":"https://doi.org/10.1007/s10787-025-01932-6","url":null,"abstract":"<p><p>Curcumin, a bioactive polyphenol extracted from the rhizome of Curcuma longa, has garnered considerable attention for its wide-ranging pharmacological properties and potential therapeutic applications. This narrative review critically synthesizes current evidence on curcumin's multifaceted biological actions, encompassing its antioxidant, anti-inflammatory, anti-cancer, and metabolic regulatory effects. Extensive preclinical and clinical studies have demonstrated that curcumin exerts beneficial effects by modulating key cellular signaling pathways and mitigating oxidative stress and inflammatory responses. Despite its promising profile, clinical translation has been hampered by issues related to low bioavailability and rapid metabolism. Recent advances in novel formulation strategies and combination therapies, however, have shown potential in overcoming these limitations. This review uniquely consolidates recent mechanistic insights with clinical translation challenges, identifying specific gaps in bioavailability research and proposing novel combination therapy approaches that distinguish it from existing curcumin reviews, ultimately facilitating evidence-based therapeutic development.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}